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ETHICAL AND LEGAL ISSUES IN SINGAPORE
BIOMEDICAL RESEARCH
Taiwo A. Oriolat
Abstract: In 2000, Singapore established the national "Bioethics Advisory
Committee" to examine the ethical, moral, social, and legal implications of life sciences
and biotechnology. The Committee will examine numerous topics, including genetic
discrimination, cloning, and stem cell research. The Committee is expected to release its
frast set of recommendations concerning stem cell research in the first half of 2002. This
paper proposes that leveraging Singapore into a world-class biomedical research center
will entail synchronizing the relevant areas of its legal ethics infrastructure and culture
with that of the major players in the global biotechnology industry. Conversely, adhering
to prevailing local ethical views will undermine its competitiveness in a field in which the
market is truly global. This hypothesis is predicated on the transient and imprecise nature
of ethics and the relative certainty of biotechnology's commercial promise in light of
post-Chakrabarty intellectual property law.
I. INTRODUCTION
Singapore is poised to become a beehive for biomedical research.2
This reflects a deliberate economic policy to diversify the electronics
dominated manufacturing sector. The Singapore government has earmarked
three billion dollars (USD 1.6 billion) to promote research and development
in life sciences. The Economic Development Board of Singapore already
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Diamond v. Chakrabarty, 447 U.S. 303 (1980). A bacterium was bioengineered to consume oil by
Ananda Chakrabarty, a biochemist with the General Electric Company. Id. The U.S. Patent Office denied
patents on the ground that no patent could be issued on a living organism, being a product of nature. Id.
On June 16, 1980, the Supreme Court held by the slim margin of five to four, inter alia, that Chakrabarty's
bacterium was not a product of nature, but a new composition of matter, the product of his ingenuity, not of
nature's. As such it was patentable under the existing law. Id.
2 Researchers at the Department of Obstetrics and Gynaecology, National University of Singapore
published the world's first report in 1994. See A. Bongso et al., Isolation and Culture ofInner Cell Mass
Cells from Human Blastocysts, 9 HUMAN REPRODUCTION 2110 (1994). The research was carried out on
twenty one donated human embryos. Id. See also Gwen Lee, Tissue Engineering: Creating and Growing
Body Parts, 2 INNOVATION 14, 15 (2001).
3 Singapore Research Centres Merge to Boost Biomedical Drive, AFP, Sept. 19, 2001, 2001 WL
25016529.
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views the budding biotech industry as a potentially crucial manufacturing
sector.4 According to the Board's joint Press Release of February 6, 2002,
the biomedical sciences industry's "manufacturing output for 2001 grew by
3.2% to SGD 6.6 billion," while "its value added grew by 3.6% to SGD 4.0
billion." Employment in the industry also grew "by 5.7% and reached
6,000," the projected manufacturing output for the sector is expected to be
SGD 12 billion by 2005. 5 Today, Singapore is a biotech haven with a
variety of international players actively engaged in both research and applied
biotechnology.
6
4 See Kwek Mean Luck, The Biotechnology Era: Ramifications of Genelabs Diagnostics v Institut
Pasteur, 13 SINGAPORE ACADEMY OF LAW J. 89 (2001).
5 "The pharmaceutical sector's output of SGD 5 billion accounted for seventy-six percent of the
total Biomedical Sciences manufacturing output and enjoyed a growth in employment of 7.6%." See Press
Release, Economic Development Board ("EDB"), Biomedical Sciences Group ("BMS Group") and
Biomedical Research Council ("BMRC") Industry Briefing (Feb. 6, 2002) [hereinafter Feb. 6 Press
Release], http://www.a-star.gov.sg/astar/upload/midl/type14/cat63/44431206Feb02BMS Briefing_
2002.doc. Medical technology grew by 3.4% in manufacturing output, and crept to SGD 1.6 billion, with
4.7% employment growth. Id.
6 For example, researchers from the National University of Singapore, the Monash Institute of
Reproduction and Development, the Hadassah Medical Center of Israel, and the Hubrecht Laboratory of
the Netherlands Institute of Developmental Biology teamed up to form a biotechnology company called ES
Cell International (ESCI) in July 2000. The Economic Development Board of Singapore and a private
investment company in Australia jointly fund ESCI. See generally Lee, supra note 2.
Furthermore, there are industry-to-industry collaborations within Singapore and across frontiers. For
instance, Gleneagles Clinical Research Center offered its services of site management and clinical
monitoring to fifty clinical trial sites in the region. Similarly, Quintiles, a local biotech company, supplies
clinical trial test kits and materials to companies conducting trials in Asia. Moreover, some foreign biotech
companies have set up shop in Singapore through their subsidiaries. These include Surromed, a US-based
company focusing on the R&D of proprietary nanotechnology-based biomedical research tools and S*Bio,
a drug company which is a joint venture between a local investment company and Chiron, a U.S.
biotechnology company. Another category includes companies that directly set up R&D centers in
Singapore. Recent examples are Eli Lilly and Novartis, two of the world's leading pharmaceutical
companies. Their research projects are expected to commence in 2002 with projected expenditures of SGD
260 million on research over five years for Eli Lilly, and SGD 220 million on research over five to ten
years for Novartis. Other biomedical companies with investments are: GlaxoSmithKline U.K., with SGD
80 million worth of a new manufacturing facilities, and Merk Sharp & Dohme, which plans to construct a
new pharmaceutical formulation facility, bringing the company's total capital investments in Singapore to
SGD 900 million. Schering-Plough (United States) is constructing a SGD 225 million lyophilisation plant
for the production of ahepatitis C drug called Interferon, and an anti-inflammatory agent for rheumatoid
arthritis called Remicade. Others are Baxter (United States) with SGD 120 million projected fixed assets
investment, and BD (United States) with SGD 25 million planned fixed assets investment. See Feb. 6 Press
Release, supra note 5.
Also, the Biomedical Research Council was established in October 2000 by the government of
Singapore. The main objectives are to support, sustain and stimulate excellent research for maintaining and
improving human health to train people in high quality research skills to meet Singapore's health needs,
quality of life and global economic competitiveness; and to promote societal awareness of biomedical
research. The Council oversees and provides support to public sector biomedical research and development
activities in Singapore. It also aims to strengthen collaborative public research in biomedical sciences. Id.
For other related materials, see Agency for Science, Technology, and Research, http://www.a-
star.gov.sg/astar/index.jsp.
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Biotechnology's main resource is living organisms. It involves
intervening in nature through varied scientific techniques to achieve a
desired result. In this respect, it is markedly different from automobile and
electronic technologies and, consequently, far more controversial. The term
"biotechnology" came into wide usage in early the 1970s, but it is not an
entirely new concept. In fact, biotechnology has been applied in cheese
making, wine fermentation, plant breeding, and animal husbandry for
centuries.
7
The use of microscopes by early scientists 8 led to the discovery of
cells in both plants and animals. 9 Cells are the factories of life that encode
the vital reproductive information of plants and animals. "Chromosomes
"
'
°0
were identified as the likely carriers of this reproductive information. They
are "threadlike" in nature and reside in the nucleus of the cell. Scientists
soon discovered that "genes" were actually located on chromosomes, and are
made from deoxyribonucleic acid ("DNA")." It subsequently became clear
that DNA is the carrier of hereditary information in plants and animals.
12 In
1953 two Cambridge University scientists, James Watson and Francis Crick,
finally deciphered the structure of DNA. They described the structure as
having "two helical chains each coiled round the same axis"'
3 and observed
that each DNA molecule comprised two sugar-phosphate backbones that
entwined one another. This shape is known as the "double helix.'
' 14 This
discovery of the structure of DNA facilitated useful insights into how DNA
7 It is said, however, that none of these techniques would qualify as "biotechnology" in the modem
sense. See ERIC S. GRACE, BIOTECHNOLOGY UNIZIPPED: PROMISES & REALITIES 2 (1997). For further
readings, see BIOTECHNOLOGY, PATENTS AND MORALITY (Sigrid Sterckx ed., 2000); BIOTECHNOLOGY:
SCIENCE, ENGINEERING, AND ETHICAL CHALLENGES FOR THE TWENTY-FIRST CENTURY (Frederick B.
Rudolph & Larry V. McIntire eds., 1996); BIOTECHNOLOGY: A HOPE OR A THREAT? (Iftikhar Ahmed ed.,
1992); LISA YOUNT, BIOTECHNOLOGY AND GENETIC ENGINEERING (2000).
8 In 1665, an English scientist, Robert Hooke, while examining plant tissue with the aid of
microscope, discovered tiny spaces surrounded by wall-like structures. GRACE, supra note 7, at 3. These
he called "cells" in his published observations. Id. He assumed that their function was to transport
substances through the plant. Id. The subsequent development and use of more powerful microscopes by
"a Dutch draper and skillful lens grinder" called Anton Van Lecuwenhock, led to the discovery 
of
microorganisms, which he called "very little animalcules." Id.
9 Id.
'0 Every living organism has a specific number of chromosomes comprising a set of almost identical
pairs (one from each parent). Id. at 10. For example, humans have twenty-three pairs of chromosomes, or
forty six in total. Id.
1 DNA comprises sugar, phosphate, and four different nitrogen-containing bases named guanine,
cytosine, thymine and adenine. Id. at 17. They are frequently expressed by the acronym: G, C, T, and A.
/d.
12 Id. at 14.
13 See J.D. Watson & F.H.C. Crick, Molecular Structure of Nucleic Acids, 171 NATURE 737 (1953)
available at http://www.nature.com/genomics/human/watson-crick/.
14 See GRACE, supra note 7, at 15.
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reproduces itself when a cell divides, and in that process, passes on a
complete copy of hereditary information to both "daughter" cells.
Scientists soon revealed the process by which hereditary information
in the DNA code was converted to proteins, the complex chemicals that do
most of the work of the cell.' 5 This process involves copying DNA into
ribonucleic acid ("RNA"), a related chemical slightly different in
composition. 16  Unlike DNA, RNA is mobile and moves from the cell
nucleus to the rest of the cell.' 7 There, the RNA shepherds the assembly of
amino acids into a protein molecule in accordance with the original DNA
specifications and instructions.' 8  In other words, genes are instructions for
making various proteins. 19 According to Eric S. Grace, 20 "every process and
product in living cells depends on proteins. They do everything from
activating essential chemical reactions, to carrying messages between cells,
to fighting infections, to making cell membranes, tendons, muscles, blood,
bone, and other structural materials." 2'
A defective or missing protein molecule is known as "genetic
mutation." 22 Genetic mutations may be rectified by "gene therapy., 23 The
ultimate genetic technology is "genetic engineering." Genetic engineering
may be used to introduce a desirable trait into plants 24 or animals, 25 to cure a
"s Id. at 18.16 The difference between DNA and RNA lies in the presence of uracil rather than thymine as one of
the four RNA bases. See YOUNT, supra note 7.7 This is known as "cytoplasm". See YOUNT, supra note 7.
18 All living things are built and run by the same types of molecules, and are fundamentally the same
at the molecular level of life where "there is no difference from a person and a bacterium." GRACE, supra
note 7, at 1.
'9 Proteins are of structural and functional importance. GRACE, supra note 7, at 21. Examples are:
collagen (found in bone and skin), keratin (makes hair and nail), fibrin (helps blood cloth), elastin (major
parts of ligaments), hormones (control body functions), antibodies (fight infection), enzymes (help speed
up chemical reactions in the body), and hemoglobin (carries oxygen in the blood). Id.20 Id. See also George Wei, Inventions, Genes And Napoleonic Victories, 9 SINGAPORE ACADEMY
OFLAWJ. 1, 59 (1997).
21 GRACE, supra note 7, at 21.
22 See Savio L.C, Woo, Gene Therapy: Beyond Genetic Diseases, in BIOTECHNOLOGY: SCIENCE,
ENGINEERING, AND ETHICAL CHALLENGES FOR THE TWENTY-FIRST CENTURY, supra note 7, at 72.
2J Id. at 74-76.
24 Such desirable traits, which are meant to increase crop yields or to accomplish a specific task,
range from resistance to drought, insect pests, diseases, or frost to herbicide tolerance. For example,
scientists at Comell University in the United States have created bananas that contain a vaccine for
hepatitis B. See Feeding The Five Billion: New Agricultural Techniques Can Keep Hunger At Bay,
ECONOMIST.COM (Nov. 8, 2001), available at http:www.economist.com/PrinterFriendly.cfn?Story_D=-
841826&CFID-2134030& 12/6/2001.
China also has made considerable advancements in genetically modified ("GM") plants that are
second only to the United States. See Tom Clarke, China Leads GM Revolution, NATURE ONLINE (Jan. 25,
2002), at http://www.nature.com/nsu/020121/020121-13.htm] (reporting that China is developing the
largest plant biotechnology capacity outside North America and that poor farmers in China are cultivating
more areas of genetically modified plants than small farmers in any other developing country). About 141
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particular genetic disease in a person,26 or for experimental purposes in
animals.27
Today, the technology is ubiquitous. It is worth billions of dollars in
global investment capital.21 It has raised as much promise as fear,29 and has
GM plants have been developed. Id. See also Jikun Huang et al., Plant Biotechnology In China, 295
SCIENCE 674, (2002).
25 For example, Aqua Bounty Farms, based in Massachusetts, has applied for Food and Drug
Administration (FDA) approval of a genetically engineered salmon that is six times the size of the normal
fish. See Sharon Tisher, Frankenfish and the FDA, BANGOR DAILY NEWS (Feb. 15, 2002), available at
http://www.bangomews.com/editorialnews/ article.html?ID=51024. In the 1980s, the gene responsible for
bovine growth hormone (somatotropin or "BST") production was successfully isolated and transferred into
bacterial cells to produce large quantities of BST. See JOHN E. SMITH, BIOTECHNOLOGY 175-76 (3d ed.
1996). When cows were injected with about thirty milligrams of BST there was significant increase in
milk production. Id.
26 For example, in a collaborative research effort, the National University of Singapore's Department
of Pediatrics, using genetic engineering, has implanted a new strand of DNA into the genetic blueprint of a
patient suffering from Duchenne Muscular Dystrophy ("DMD"), a fatal muscle wasting disease. See
National University of Singapore, Altering Genes to Save Lives, http://www.nus.edu.sg/corporate/
research/gallery/research5.hm. The new DNA stopped the production of the defective gene, and induced
the production of a partially functional dystrophin, leading to a considerable improvement that was less life
threatening to the patient. Id.
Similarly, on September 26, 2000, the cells from the cord blood of a new born baby, Adam Nash, was
transplanted into Molly his sister, who was suffering from fanconi's anemia, a fatal genetic disease. See
Rick Weiss, Test Tube Baby Born to Save Ill Sister, WASH. POST, Oct. 3, 2000. In February 2002, the
Fertilization and Embryology Authority in the United Kingdom ruled that a couple could use this technique
to create a designer baby. See "Designer Baby'" Row Couple Defend Decision, ANANOVA, Feb. 24, 2002,
at http://www.ananova.com/ youmews/story/sm_528603.html. Embryos will be screened to ensure that the
next baby is genetically identical to the couple's son. Id. The baby's umbilical cord cells will be
transplanted into the bone marrow of their son, who suffers from a potentially fatal disease called
"thalassaemia." Id. This decision has drawn much criticisms in and from outside the United Kingdom. Id.
27 An example is the "Harvard Oncomouse," a mouse genetically engineered to be susceptible to
cancer by researchers at Harvard Medical School. See Ex Parte Allen, 2 U.S.P.Q.2d (BNA) 1425 (1987).
The feat was accomplished by exploiting transgenic technology to insert the myc oncogene tied to a
mammary-specific promoter into the new embryo of a normal mouse. Id. Also, scientists at the Roslin
Institute, Edinburgh, Scotland, successfully cloned a sheep, "Dolly," by a nuclear transfer from a cultured
cell line of adult and fetal mammalian cells. See K.H.S. Campbell et al., Sheep Cloned By Transfer From A
Cultured Cell Line, 380 NATURE, 64 (1996). The feat took the world by surprise, raising speculation that
human cloning was afoot. Id. See also I. Wilmut et al., Viable Offspring Derived From Fetal And Adult
Mammalian Cells, 385 NATURE, 810 (1997).
28 For instance, the world market for pharmaceutical biotechnology by 2004 will be an anticipated
EUR 506 billion, while the global market for industrial biotechnology (only partly biotech) will be an
anticipated EUR 1.5 trillion by 2010. See BJORN THEGEBY, LIFE SCIENCES AND BIOTECHNOLOGY-A
STRATEGY FOR EUROPE, COMMUNICATION FROM THE COMMISSION To THE COUNCIL, THE EUROPEAN
PARLIAMENT, THE ECONOMIC AND SOCIAL COMMITTEE OF THE REGIONS, 7 (2002), http://europa.eu.int/
eur-lex/en/com/cnc/ 2002/com2002 0027en01.pdf. Also the market capitalization of Europe's public
biotechnology companies is estimated at EUR 75 billion, while that of the United States is EUR 376
billion. See J. SENKER ET AL., FINAL REPORT: EUROPEAN BIOTECHNOLOGY INNOVATION SYSTEMS, 54
(2001 http://www.susex.ac.uk/spru/biotechnology/ebis/ebisfinalreport.pdf.(2 The promise is of tackling incurable and intractable diseases, such as diabetes and Parkinson's,
and boosting global food production, while the ethical, moral and environmental fears are of human
cloning, life and gene patenting, gene pollution, and safety concerns. See GRACE, supra note 7; see also
Sean D. Murphy, Biotechnology and International Law, 42 HARV. INT'L L.J. 47, 47-59 (2001).
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sparked a global ethical, moral, and political debate on issues ranging from
genetically engineered crops to stem cell research and human cloning. 3°
Perhaps the most hotly contested spheres of modem biotechnology are
biomedical and biopharmaceutical research and applications, which depend
primarily on plant, animal, and human genetic materials. 31 First there is the
problem of plant and animal genetic resource control and access, which
predominates the trade and political discourse. 32  Second, biomedical
30 For instance, the European Union's continual ban on GM food imports on safety grounds from the
United States and Canada, despite the World Trade Organization ("WTO") ruling on its impropriety could
escalate to the biggest trade dispute ever, and would surely dwarf the banana wars in its full ramifications.
See GMO Update: EU Labeling of GMOs; Brazil: Thailand, BRIDGES WEEKLY TRADE NEWS DIG. (July 31,
2001), http://www.ictsd.org/html/weekly/31-07-01/story5.htm. The European Union's ban has been in
place since 1998 and is likely to remain for another two years, while the EU member states continue to
debate proposed labeling and traceability regulations, according to EC Environment Commissioner, Margot
Wallstrom. Id. The U.S. Trade Representative (USTR) Robert Zoellick had described the EU approach as
founded on "fears and lack of a scientific basis or knowledge." See BRIDGES WEEKLY TRADE NEWS DIG.
(Jan. 24, 2002).
31 Accessing genetic resources goes to the heart of the North/South dispute on fashioning a concrete
agenda for the preservation of the biodiversity. Developing countries feared that transgenic plants and
animals would eventually deplete biodiversity and create an unprecedented corporate control over
transgenic beings mainly through the instrumentality of patent laws. The specter of poor farmers paying
royalties for transgenic seeds has been deprecated as a regime designed to make "bioserfs" out of the
farmers. This problem is by no means peculiar to farmers from developing countries. For example, in
March 2001, Monsanto, a multinational agro-biotechnology company, successfully sued an elderly
Saskatchewan farmer in Canada, Percy Scfmeiser, for patent infringement. See Monsanto Canada, Inc. v.
Schmeiser, [2001] F.C. 256, available at http:/decisions.fct-cf.gc.ca/fct/2001/2001fct256.html. The
company contended that the farmer had illegally planted and sold harvested seed containing the gene and
cells covered by Monsato's patent on Roundup Ready Canola. Id. There have been increasing calls for the
harmonization of the principles of the Agreement on Trade Related Aspects of Intellectual Property Rights
("TRIPS" agreement) with that of the Rio Biodiversity Convention in the context of acknowledgement of
the source, and compensation for the use of genetic resources in biotechnology inventions. See generally
VANDANA SHIVA, PROTECT OR PLUNDER: UNDERSTANDING INTELLECTUAL PROPERTY RIGHTS (2001).32 See supra note 31 and accompanying text. See also Philippe Cullet, Property Rights Over
Biological Resources: India's Proposed Legislative Framework, 4 J. WORLD INTELL. PROP. 211, (2001);
Ehsan Masood, Social Equity Versus Property: Striking The Right Balance, 392 NATURE, 537 (1998). For
instance, India, China, Brazil and nine other of the world's most biodiverse countries signed an alliance on
February 18, 2002 to fight biopiracy and ensure the preservation of their peoples' right to their genetic
resources. See Virginia Gewin, Poor Nations Seek New Biodiversity Deal, 415 NATURE, 949 (2002). The
twelve nations, which also include Indonesia, Costa Rica, Colombia, Ecuador, Kenya, Peru, Venezuela, and
South Africa, comprise 70% of the world's biodiversity. Id. Dubbed the "Group of Allied Mega-
Biodiverse Nations," the alliance is bent on promoting its cause at the U.N. World Summit on Sustainable
Development to be held in Johannesburg, South Africa in August 2002. Id. See also Mark Stevenson,
China, Brazil, India, 9 Other Nations Form Alliance Against Biopiracy, ASSOCIATED PRESS, Feb. 19, 2002,
http://www.enn.com/news/wire-stories/2002/02/02192002/ap_46427.asp. See also Anne Marie Ruff,
Guarding the Region's Riches, FAR E. ECON. REV., Jan. 31, 2002, available at 2002, WL-FEER 5169463.
It is based on the interview granted by a Thai lawyer, on the best way to protect Thai local traditional
knowledge and products, especially the "jasmine rice" on which researchers from the United States have
allegedly been preying. See also Susan Young, The Patentability of Maori Traditional Medicine And The
Morality Exclusion In The Patents Act 1953, 32 VICTORIA U. WELLINGTON L.R. 255 (2001) (making the
case for the protection of Maori traditional medicine and exploring the suitability of the New Zealand
patents law for this purpose).
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research and clinical applications raise ethical, moral, and legal issues posed
by gene patenting, human genetic sourcing, 33 ownership and theft of genetic
materials or body parts, genetic discrimination, genetic screening and
confidentiality, stem cell research, and human cloning.34 Of particular
concern is embryonic stem cell research, which has brought the concept of
"personhood" to the forefront of bioethics discourse in countries around the
world.35
Using a comparative analysis, this Article will explore the hypothesis
that ethical views on biomedical research in Singapore are bound to be as
disparate as in other countries. Also, this Article proposes that Singapore
must align its ethical and legal views with that of the other leading
biotechnology nations in order to maintain its competitive standing.
At its conclusion, this Article examines the driving force behind
biotechnology inventions, intellectual property law, and the relative
weakness of countervailing trends in bioethics. From Chakrabarty36 to
Harvard Oncomouse,37 the tilt in favor of modern biotechnology is palpable.
Consequently, the fortune and future of biomedical research in Singapore
depends more on intellectual property than on the vagaries of ethics.
II. SETTING THE STAGE FOR ETHICAL AND LEGAL ISSUES IN SINGAPORE
BIOMEDICAL RESEARCH
The "Bioethics Advisory Committee" ("Committee") was established
by Singapore in December 2000 to address the ethical and social issues
33 Central to the issue of human genetic sourcing for biomedical research are the prohibition against
commercialization of human body parts and the necessity for patients' informed consent in pre- and post-
operative body parts excision. See, e.g., Moore v. Regents of the Univ. of Cal., 793 P.2d 479, (Cal. 1990).
The Supreme Court of Califomia held that there was a breach of fiduciary duty or lack of informed consent
based on allegations that a physician concealed his economic interest in postsplenctomy takings of blood
and other samples for use in research when the physician failed to disclose that he had begun to investigate
and initiate procedures for obtaining a patent on cell line developed from the patient's cells. Id. The court
however held that Moore had no part in the proceeds of the patented cell line, since he could not, in law,
own the excised body parts from which the cell line was isolated. Id. This was essentially a policy
decision-ostensibly to facilitate unhindered medical research. Id.
34 See Kaan Terry Sheung-Hung, Rights, Ethics And The Commercialization Of The Human Body,
SING. J. LEGAL STUDIES 483, (2001); LORI ANDREW & DOROTHY NELKIN., BODY BAzAAR: THE MARKET
FOR THE HUMAN TISSUE IN THE BIOTECHNOLOGY AGE (2001); Catherine Keller, Playing God, in BORN
NOT MADE: THE TROUBLING WORLD OF BIOTECHNOLOGY (Casey Walker ed., 2001).
35 See Sahin Aksoy, Personhood: A Matter of Moral Decisions, 7 EUBOIS J. AsIAN & INT'L
BIOETHICS, 3 (1997); Keller, supra, note 34.
36 Diamond v. Chakrabarty, 447 U.S. 303 (1980).
37 The 2001 Harvard Oncomouse European Patent Office decision limited the scope of the patent
claims from transgenic mammals to mice. See European Patent Office Limits Harvard Oncomouse Patent,
at www.european-patent-office.org/news/pressrel/ 2001_11_07e.htm. Ethical issues were apparently
glossed over. See id.
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associated with biomedical sciences. It has the duty of ensuring that the
science is set on the path of excellence and "high ethical and legal
standards. 38  The Committee is to be guided by the imperative for the
protection of "the rights and welfare of individuals" without diminishing the
prospect for the realization of biomedical science's full potential for growth
in Singapore. 39  This is essentially a balancing act that underscores the
government policy of making Singapore a beehive for life sciences
research.4 °
The policy is neither new, nor unique to Singapore. Both Taiwan and
South Korea have also made biomedical research a national priority.4' Basic
research is essential to reaching the goal of biotechnology transfer.42  Of
equal importance to a pro-biotechnology strategy is a viable intellectual
property regime and a judiciary versed in the technical intricacies of patent
litigations. The patent law in Singapore is substantially compliant with the
Agreement on Trade-Related Aspects of Intellectual Property Rights
("TRIPS"), 43 while the judiciary's thorough grasp and understanding of
patent litigation was demonstrated in Singapore's first ever biotechnology
patent litigation, Genelabs Diagnostics v. Institute Pasteur.
44
III. THE MORALITY AND "ORDRE PUBLIC" BAR EXCEPTIONS TO
BIOTECHNOLOGY PATENTS 0
Patent law has the narrow purpose of protecting property rights to
technological inventions. The ethical or moral propriety of patenting living
things45 is beyond the scope of the Committee's briefs. In fact, denying
38 This construct is based on the information on the Committee's website, at http://www.bioethics-
singapore.org/bac/introduction.jsp.
9 Id.
40 See supra notes 2, 5, and accompanying text.
41 See ROBERT T. YUAN, BIOTECHNOLOGY IN SINGAPORE, SOUTH KOREA AND TAMWAN 5 (1988).
42 Id.
43 See Patents Act, No. 21, 1994 (as amended by Patents (Amendment) Act, No. 40, 1995) (Sing.).
The Marrakech 1994 TRIPS agreement was a WTO trade based instrument that required a minimum level
of intellectual property protection by WTO member countries. See Agreement on Trade-Related Aspects
of Intellectual Property Rights, Apr. 15, 1994, available at www.wto.org/english/tratope/tripse/
tagm0_e.htm [hereinafter TRIPS].
Genelabs Diagnostics v. Institute Pasteur, [2000] 1 SLR 121, 2000 SLR Lexis 61. The Court of
Appeal, while affirming the High Court Judgment, upheld the validity of Genelabs' patent in its HIV
diagnostic kits (Genclabs Diagnostics HIV-2 Westem-Blot Version 1.2 ("Blot 1.2") and Genelabs
Diagnostics HIV Blot 2.2 ("Blot 2.2")). Id. The patent had been challenged mainly on grounds of lack
novelty and obviousness. Id. at 14. For a discussion on the full ramifications of the decision for the
budding biotechnology industry in Singapore, see Luck, supra note 4.
4 The prevailing moral and ethical objections to the patentability of living things are anchored on
their being products of nature. See BIOTECHNOLOGY, PATENTS, AND MORALITY, supra note 7. If a
VOL. I11 No. 3
SINGAPORE BIOMEDICAL RESEARCH
patentability to genetically engineered life forms, mainly on ethical and
moral grounds, could be antithetical to the realization of biomedical
science's full potential in Singapore and elsewhere. Article 13 of
Singapore's Patents Act provides thus:
(3) An invention the publication or exploitation of which
would be generally expected to encourage offensive,
immoral or anti-social behavior is not a patentable
invention.
(4) For the purposes of subsection (3), behavior shall not be
regarded as offensive, immoral or anti-social only because
it is prohibited by any law in force in Singapore.46
The Japanese Patent Law has similar terms in article 32, which
defines unpatentable inventions as "the inventions liable to contravene
public order, morality, or public health ....47 However, in both Singapore
and Japan the key statutory terms are undefined. Consequently, courts and
patent examiners are left to set the parameters of public order and morality.
For example, European courts have addressed the meaning of "public
order" and "morality" when interpreting article 53(a) of the European Patent
Convention ("EPC"), which is in pari materia with article 13(3) of
Singapore's Patent Act and is similar to article 32 of Japan's Patent Law.
The European Patent Office ("EPO") Board of Appeal, in Plant Genetic
Systems v. Greenpeace, defined ordre public as follows:
It is generally accepted that the concept of "ordre public"
covers the protection of public security and the physical
integrity of individuals as part of society. This concept
encompasses also the protection of the environment.
Accordingly, under Art 53(a) EPC, inventions the exploitation
of which is likely to breach public peace or social order (for
example, through acts of terrorism) or to seriously prejudice the
environment are to be excluded from patentability as being
Contrary to public policy. 48
particular gene is isolated from nature and patented, its functionality still depends on the inherently
regenerative nature of the whole organism, the scope of which is well beyond the patented gene. Id.
46 Patents Act, art. 13(3) & (4).
47 See Japan Patent Law, Law No. 121 of 1959 (as amended by Law No. 220 of 1999), art. 32
(entered into force in January 6, 2001.).
48 Plant Genetic Systems v. Greenpeace, [1995] E.P.O.1R 357.
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The EPO defined morality in the same case as follows:
The concept of morality is related to the belief that some
behavior is right and acceptable whereas other behavior is
wrong, this belief being founded on the totality of the accepted
norms which are deeply rooted in a particular culture. For the
purposes of the EPC, the culture in question is the culture
inherent in European society and civilization. Accordingly,
under Article 53(a) EPC, inventions the exploitation of which is
not in conformity with the conventionally accepted standards of
conduct pertaining to this culture are to be excluded from
patentability as being contrary to morality.
49
The relevance of pan-European cultural standards in gauging the
morality of biotechnology inventions is doubtful in the context of today's
global economy. 0 It appears irreconcilable with the notion of universal
intellectual property standards embodied in the TRIPS agreement. 51 How
differently would people in Asia, America, Africa, and Europe view genetic
engineering, stem cell research, and patents on living organisms? There is a
growing body of empirical evidence supporting the concept of "universal
bioethics. 52
Though it is not within the scope of this Article, the following
examples underscore the nearly universal approach to the ethical and moral
dilemmas posed by embryonic stem cell research:
In Singapore, the Committee has recommended the
establishment of a Statutory Board to regulate and monitor
embryonic stem cell research, while human cloning has been
prohibited.53
49 Id.
so See KEITH E. MASKUS, INTELLECTUAL PROPERTY RIGHTS IN GLOBAL ECONOMY 3-6 (2000).
51 See TRIPS, supra note 43.
52 A survey conducted in the United States, Australia, Singapore, Japan, India, Thailand, New
Zealand, Hong Kong, the Philippines, Israel, and Russia examining attitudes about biotechnology revealed
that "people in different countries share very similar images of life and similar diversity of views on most
of these issues on bioethics associated with genetics. ... [T]he range of choices people desire is
transcultural. ... See Darryl Macer, Bioethics and Genetics in Asia and the Pacific: Is Universal
Bioethics Possible?, in CHANGING NATURE'S COURSE: THE ETHICAL CHALLENGE OF BIOTECHNOLOGY 183
(1996).
53 See Chan Kay Min, Statutory Board Right Move: Stem-Cell Researchers, STRAITS TIMES
INTERACTIVE, Jan. 14, 2002, at http://straittimes.asial.com.sgcybemews/story/0,1870,96409-
1011045540,00 .html?.
VOL. I11 No. 3
SINGAPORE BIOMEDICAL RESEARCH
In the United Kingdom, the House of Lords Select Committee
on stem cell research has recommended that research on human
embryonic stem cells should be allowed under strictly
controlled conditions.
54
In Taiwan, human cloning in stem cell research was banned, but
the health authorities were inclined to allow limited embryonic
stem cell research.
55
In Germany the importation of embryonic stem cell lines
created before January 30, 2002 is now permitted, while
research must be conducted under prescribed conditions.56
In the United States, human cloning has been prohibited by
several states, while the Bush administration only allows
limited federal funding for embryonic stem cell research under
prescribed conditions.57
On February 25, 2002, the United Nations Ad Hoc Committee
On The Convention To Ban Human Cloning met for the first
time, and heard expert views on the science and ethics
involved.
58
These examples depict a unanimous, universal, and spontaneous response
favoring limited embryonic stem cell research for therapeutic purposes,
while foreclosing human cloning. There is nothing to suggest that this
54 See Go-ahead for UK Stem Cell Research, GUARDIAN UNLIMITED, Feb. 27, 2002, at
http://www.guardian.co.uk/genes/article/0,2763,658943,00.html.
55 The health authorities feared that an outright ban could stymie the development of Taiwan's
nascent biotechnology sector. See Taiwan Bans Human Cloning in Stem Cell Research, REUTERS, Feb. 20,
2002, available at http://ca.news.yahoo.com/020220/5/jmx8.hm-l.
56 See Quirin Schiermeier, German Parliament Backs Stem-Cell Research, 415 NATURE 566 (2002),
available at http://www.nature.com/cgi-taf/DynaPage.taf~file=/nature/journal/v4l5/n6872/full/41566a .
57 The House of Representatives voted to ban human reproductive and therapeutic cloning in July
2001 in a 265-162 vote. Declan McGulagh, Senate's Turn in Clone Zone, WIRED, Feb. 9, 2002, at
http://www.wired.com/news/print/0,1294,50297,00.html. The measure stated that "it shall be unlawful for
any person or entity ... to perform or attempt to perform cloning or import a cloned human embryo ......
Human Cloning Prohibition Act of 2001, H.R. 2505, 107th Cong. § 302 (2001). The penalties would have
been up to ten years in prison and a USD I million fine. Id.
Committee Charged with Elaborating Convention to Ban Human Cloning Concludes First Session
at Headquarters, UN NEWS SERVICES/PRESS RELEASES, at http://www.un.org/News/Press/docs/2002/
12996.doc.htm (Mar. 1, 2002).
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uniformity of views on embryonic stem cell research is either immutable or
representative of the global overall perception of biotechnology industry.
59
It does, however contradict the culture-specific notion of morality espoused
by the EPO in Greenpeace.
In the absence of guidance from Parliament, any number of morality
objections might arise. For example, Singapore might recognize a cause of
action challenging the validity of a patented cell line obtained from a stolen
embryo. Similarly, a plaintiff might challenge the validity of a patented cell
line derived, as in Moore, without the informed consent of the donor.
60
Although the plaintiff in Moore did not challenge the validity of the patented
"Mo cell line," his claim to share in the proceeds of the invention derived
from his cells, with a "potential market of approximately USD 3.1 billion by
the year 1990," was declined. Based on California law, he had no ownership
in his excised cells, and the patented cell line was "both factually and legally
distinct from cells" originally taken from his body.61 The Moore decision
vindicated the underlying policy of ensuring unhindered medical access to
human cells and other genetic materials for basic research and clinical trials.
Though Moore was fought on grounds other than morality, a plaintiff
in Singapore could arguably challenge the validity of a patent under section
13(3). It is the Intellectual Property Office of Singapore ("IPOS") or the
Court's prerogative to decide whether the publication or exploitation of an
invention would "encourage offensive, immoral, or anti-social behavior." It
is most likely that, faced with a Moore scenario, Singapore's patent
examiners or Courts would find the underlying policy in Moore to be more
compelling.
Article 53(a) of the European Patent Convention,62 like section 13(3)
of Singapore's Patent Act, has no guidelines for delimiting the concepts of
"ordre public" and "morality," except as interpreted by the European Patent
Office Board of Appeal in the Greenpeace decision.6 Rainer Moufang has
suggested that article 53(a) could be used to challenge the patentability of an
invention on ethical grounds, if the sole purpose of the patent application is
the invention's commercialization. 64 However, vitiating a patent on the
59 Opinions still differ largely on other aspects of biotechnology such as patents on living organisms,
genetically modified crops, etc. See SHIVA, supra note 31.
60 Moore v. Regents of the Univ. of Cal., 793 P.2d 479 (Cal. 1990).
61 Id. at 141.
62 Convention on the Grant of European Patents, Oct. 5, 1973, art. 53(a), available at http://www.
european-patent-office.org/legal/epc/e/ma I.html [hereinafter European Patent Convention].
63 Plant Genetic Systems v. Greenpeace, [1995] E.P.O.R. 357, 366.
6 See Rainer Moufang, Patenting of Human Genes, Cells and Parts of the Body?-The Ethical
Dimensions of Patent Law, 25 INT'L REV. INDUSTRIAL PROP. & COPYPGHT L. 507 (1994).
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basis of this reasoning could be problematic. It is axiomatic that patent
monopoly is a means to an end. The end is an exclusive commercial
exploitation either by operating and producing the invention, or through
franchises and licenses. 6F In other words, the patent law system presumes a
commercial motivation.
66
The circumstances under which article 53(a) may be invoked by
patent examiners is contained in the Guidelines for Examination in the
European Patent Office: "This provision is likely to be invoked only in rare
and extreme cases. A fair test to apply is to consider whether it is probable
that the public in general would regard the invention as so abhorrent that the
,67grant of patent rights would be inconceivable."
It is Sigrid Sterckx's view, however, that this guideline failed to
stipulate the modality for discovering the attitude of "the public in general"
towards the invention at issue. 68  This concept raises several questions.
Would this be through a referendum or opinion polls? Would it be the
prevailing "attitude of the public" in the corporate E.U. or in individual
member states? Do we evaluate the general attitude of the entire public or
just a segment (e.g., molecular biologists, professional ethicists, religious
leaders, or ecologists)? How would the objectivity of these groups be
assessed? What if public attitude differs from one country to the other or
even within a country? Would referendums or opinion polls not derogate
from the patent examiner's or court's authority in deciding what a patentable
invention is? The problem could be further exacerbated if the invention in
question has some political or religious coloration, or if public attitude is
evenly divided.
These questions surfaced in Howard Florey, the "Relaxin case."69 In
Howard Florey, the EPO had, over strong opposition, allowed a patent for
the genetic engineering of DNA from a pregnant woman's body for the
production of H2-relaxin. It was contended that this was nothing short of
patenting human life. 70 The objections were dismissed on the grounds, inter
65 See WILLIAM R. CORNISH, INTELLECTUAL PROPERTY: PATENTS, COPYRIGHT, TRADEMARKS AND
ALLIED RIGHTS 117-18 (4th ed. 1999).
6 Some scholars have hotly challenged this notion. See, e.g., David Vaver, Some Agnostic
Observations On Intellectual Property, 6 INTELL. PROP. J. 125, 127 (1990-91) ("[I]ntellectual property
regimes are said to encourage the initial creative act. Yet, in the centuries before copyright and patent laws
were established or rigorously enforced, inventive and creative work flourished.").
67 European Patent Office, Guidelines for Examination in the European Patent Office, pt. C, ch. IV,
3.1, available at http://www.european-patent-office.org/legal/guilines/pdf/gui_e-full.pdf.
68 See Sigrid Sterckx, European Patent Law and Biotechnological Inventions, in BIOTECHNOLOGY,
PATENTS AND MORALITY, supra note 7, at 26-27.
6' Howard Florey v. Fraktion der Grunen Im Europaischen Parlament; Lannoye, [1995] E.P.O.R.
541 [hereinafter Howard Florey].
70 See CORNISH, supra note 65, at 230.
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alia, that DNA was not "life," but rather a substance carrying genetic
information for the production of medically useful protein. In dismissing the
slavery contention, the EPO found:
[A]s for the opponent's assertions concerning slavery and
dismemberment of women, these are considered to betray a
fundamental misunderstanding of the effects of a patent. It can
not be overemphasized that patents covering DNA encoding
human H2-relaxin, or any other human gene do not confer on
their proprietors any rights whatever to individual human
beings any more than do patents directed to other products such
as proteins, including human H2-relaxin. No woman is affected
in any way by the present patent-she is free to live her life as
she wishes and has exactly the same right to self-determination
as she had before the Patent was granted . . . . [T]he
exploitation of the invention does not involve dismemberment
and piecemeal sale of women. The whole point about gene
cloning is that the protein encoded by the cloned gene-in this
case human H2-relaxin-is produced in a technical manner
from unicellular hosts containing the corresponding DNA; there
is therefore no need to use human beings as a source for the
protein. The only stage at which a woman was involved was at
the beginning of the making of the invention, as a (voluntary)
source for Relaxin mRNA.7 '
Assuming, arguendo, that the EPO was correct, the analysis did not
address the morality of Relaxin's commercial exploitation. This is
symptomatic of the increasing tensions and conflicts between ethical or
moral considerations and the commercialization of biotechnology. It is a
contemporary conflict in which ethical and moral influences are, at best,
tenuous.
During trial, the opponents had requested that a referendum be
conducted on the issue. In rejecting the proposition the Opposition Division
declared:
[T]he opponents requested that the EPO carry out a referendum
.... This request is refused since in opposition proceedings the
burden of proof lies with the opponent-if they felt that such a
71 Howard Florey, [1995] E.P.O.R. at 550.
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survey might assist their case, it was up to them to carry it out.
In any case, the Opposition Division wishes to point out that
even if such a Referendum were feasible, there is no provision
in the EPC that only those inventions actively approved by the
public should be patented. If such a provision existed, it is
arguable that the number of patents Grants would be decimated
.... [O]nly in those very limited cases in which there appears
to be an overwhelming consensus that the exploitation.., of an
invention would be immoral may an invention be excluded
from patentability under Art. 5 3(a).72
This argument begs the question. It offers no insight into what constitutes
an "overwhelming consensus," and how it could be fairly ascertained. Even
if it were possible to have "an overwhelming consensus," the EPO would
most likely dismiss it as a non-EPC requirement for patentability of
inventions or as indecisive of such patentable subject matter as it found in
Greenpeace.73 This stance underscores a pro-patent policy that the EPO was
not ready to leave to the whims of an increasingly skeptical public.
This EPO pro-patent policy was clearly manifested in Greenpeace
where the EPO dismissed a public survey showing opposition to genetically
modified herbicide resistant plants.74 A patent for such plants had been
granted to Plant Genetic Systems. The opponent, Greenpeace, presented a
survey of opinion polls among farmers in Sweden and Switzerland, in which
a large majority of Swedish farmers were against herbicide resistant crops.
In Switzerland, 69% of the respondents to opinion polls objected to patents
on plants and animals. In rejecting the survey, the EPO Board of Appeal
held that the survey "can scarcely be considered decisive per se when
assessing patentability of a given subject matter with regard to the
requirements of article 53(a) EPC ....,7 The Board predicated its views,
inter alia, on grounds that: surveys and polls could fluctuate within short
periods, could be very easily influenced, and would not necessarily reflect
ordre public and morality, and that the "morality assessment" had to be
made on a case-by-case basis.76
These findings obviously challenge the probative value of opinion
polls. How then can public attitude be determined? The EPO had
72 Id. at 553.
73 Plant Genetic Systems v. Greenpeace, [1995] E.P.O.R. 357, 373.
74 Id. at 369.
71 Id. at 368.
76 Id. at 369.
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apparently hinted in Howard Florey that the opposition could use a survey to
demonstrate general opposition to a particular class of patents. 7
In delimiting the scope of ordre public of article 53(a) in Greenpeace
the EPO Board of Appeal had noted that acts that are inimical to the
environment would be considered violations.78  But challenging a
biotechnology invention on environmental grounds would require conclusive
scientific evidence. The EPO, while noting the absence of such evidence in
Greenpeace, found as follows:
The Opponent's inability to prove the extent of the risks ... is
hardly surprising since experts all over the world have for at
least the past fifteen years been intensively addressing
themselves to the question of possible risks associated with
genetic engineering and in particular with the release of
genetically engineered organisms into the wild. Despite all this
effort, there is still no agreement concerning the extent of these
risks and the Opponent has indeed conceded that the risks are
impossible to determine with certainty .... [I]t is difficult to
see how examiners could ever be in a position to take a stand on
such questions .... If examiners were to attempt to do so, the
result could only be arbitrary and superficial and thus unfair to
applicants.79
This finding quite predictably weighed unduly in favor of
biotechnology patenting. The pertinent question is whether a particular
technology poses a threat to the environment. Securing unanimity of
scientific views on the effect of the release of genetically engineered
organisms into the wild is virtually impossible, due to individual and
industry vested interests. In a situation where an ecologist would readily
disagree with a molecular biologist, and a basic researcher generally is more
cautious than the clinical physician or industrial scientist, a convergence of
opinion on topical biotechnology issues is extremely unlikely.80
77 Howard Florey, [1995] E.P.O.R. at 552. ("Obviously recognizing that the EPO is not the right
institution to decide on fundamental ethical questions, the opponents requested that the EPO carry out a
referendum to find out what the public in the Contracting States really wants to be patented. This request is
refused since in opposition proceedings the burden of proof lies with the opponent-if they felt that such a
survey might assist their case, it was up to them to carry it out.").
8 Plant Genetic Systems v. Greenpeace, [1995] E.P.O.R. at 369.
79 id.
go It has been suggested that science is ethically neutral; while motivations for scientific research
were listed in order of priority as: self-actualization, self-esteem, or individual ego; concern for society
needs; the need for personal economic and emotional security; and the actual scientific urge that drives
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The EPO's pro-patent stance is not without precedent. The Supreme
Court of the United States had earlier charted the same path in Diamond v.
Chakrabarty.8 1  In Chakrabarty, the respondent had filed a patent
application for the invention of a bacteria, pseudomonas, stably transformed
with plasmids that allowed the bacteria to degrade oil.8 2  The carbon
containing genes for hydrocarbon degradative pathways are not found
naturally in pseudomonas in the environment."3  This invention was
designed for bioremediation of oil spills. The Court held, inter alia, that a
genetically engineered microorganism is not a product of nature, but rather a
product of a person's work, and thus is patentable. In dismissing the
argument that the invention would adversely affect the environment, the
Court held:
We are told that genetic research and related
technological developments may spread pollution and disease,
that it may result in a loss of genetic diversity, and that its
practice may tend to depreciate the value of human life .... It
is argued that this court should weigh these potential hazards in
considering whether respondent's invention is patentable
subject matter ....
We disagree . . . . We are without competence to
entertain these arguments--either to brush them aside as
fantasies generated by fear of the unknown, or to act on them.
The choice we are urged to make is a matter of high policy for
resolution within the legislative process after the kind of
investigation, examination, and study that legislative bodies can
provide and courts cannot .... Whatever their validity, the
contentions now pressed on us should be addressed to the
political branches of the Government, the Congress and the
Executive, and not to the courts.84
But would the court have declined "competence to entertain these
arguments" if they had been supported by scientific evidence? Did the
issues really call for legislative intervention or was this a shirking of judicial
research scientists. See K.P. Kochhar, What Has Ethics Got To Do With Research?, 9 EUBIOS J. ASIAN &
INT'L BIOETHIcs 163. This order of priorities was said to have led "to acute pervasive and intractable
dilemmas." Id.
81 Diamond v. Chakrabarty, 447 U.S. 303 (1980).
2 Id. at 305.
83 id.
84 Id. at 316-17.
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responsibility? It should be noted that the United States Patent Act85 has no
language equivalent to section 13(3) of Singapore's Patent Act, Article 53(3)
of the EPC, or section 32 of Japanese Patent Law. The United States
Supreme Court relied on section 101 of the Patent Act, which defines
patentable inventions as follows:
Whoever invents or discovers any new and useful process,
machine, manufacture, composition of matter, or any new and
useful improvement thereof, may obtain a patent therefor,
subject to the conditions and requirements of this title .... 6
The statute is silent on morality. The Court, while interpreting the
section, held inter alia that Congress intended statutory subject matter to
include "anything under the sun made by man" as long as it is a "new and
useful process, machine, manufacture, composition of matter ...."87
Undoubtedly, the bacterium was new and useful; but assuming that there
was some cogent scientific evidence before the court highlighting the
potential adverse effects of the bacterium on the environment and public
health, would the court have deemed this sufficient to negate the invention's
usefulness? The Court would obviously be serving public interest by
rejecting patents for inventions whose usefulness to society would be
overwhelmed by specific detrimental effects. Or would the Court still defer
to Congress? This was definitely a policy decision, and the Court has passed
on numerous policy judgments in the past.88
85 See Patent Act, 35 U.S.C. §§ 101-376 (2002).
16 35 U.S.C. § 101.
87 Diamond v. Chakrabarty, 447 U.S. 303, 309, 307 (1980). Note, however, that apart from
satisfying section 101, the requirements of novelty and non-obviousness under sections 102 and 103 must
be met. See 35 U.S.C. §§ 102-103.
88 For instance, in Feist Publ'ns, Inc. v. Rural Telephone Serv. Co., 499 U.S. 340, 353 (1991), the
Supreme Court rejected the "sweat of the brow" doctrine earlier espoused by the Southern District of New
York in Jeweller's Circular Publ'g Co. v. Keystone Publishing, 281 F. 83 (S.D.N.Y. 1922), and denied
originality to Rural's copyright claims in their White pages telephone directory. The Southern District of
New York held:
The right to copyright to a book upon which one has expended labor in its preparation does not
depend upon whether the materials ... are public juris, or whether such materials show literary
skill or originality, either in thought or in language, or anything more than industrious collection.
The man who goes through the streets of a town and puts down the names of each of the
inhabitants, with their occupations and their street number, acquires materials of which he is the
author.
Id. at 88. In Feist Publications, Justice O'Connor observed that the "sweat of the brow" doctrine
effectively eroded the principle that no one could copyright facts or ideas. 499 U.S. at 353. The underlying
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It would be interesting to know if the Court would still uphold
Chakrabarty in light of the TRIPS agreement. Articles 27(1) & (2) of the
TRIPS agreement are essentially analogous to both sections 13(3) & (4) of
Singapore Patent Act and Article 53(a) of the EPC. The most likely
outcome is that the morality provisions of TRIPS would take a back seat to
the pro-invention policy embedded in U.S. patent law.
How would Greenpeace, Howard Florey, and Chakrabarty be
resolved in Singapore? Singapore has an explicit policy promoting
biotechnology. Further, there is no prohibition in Singapore against patents
for animal or plant varieties, or biological process for the production of
animals or plants. 89 In the United Kingdom, plant varieties are protected
against patenting by the Plant Varieties and Seed Act, 90 while the EPO
Examining Division in Harvard Oncomouse excluded animal varieties from
patentable inventions ostinsibly on moral and ethical grounds.9' But events
in the United States since Chakrabarty seem to have influenced European
Union policy on animal patenting as demonstrated by Oncomouse. The
patent's principal claims were:
1. A method for producing a transgenic non-human
mammalian animal having an increased probability of
developing neoplasms, said method comprising
introducing an activated oncogene sequence into non-
human mammalian animal at a stage no later than the
eight-cell stage.
2. A transgenic non-human mammalian animal whose germ
cells and Somatic cells contain an activated oncogene
sequence introduced into said animal, or an ancestor of
said animal, at a stage no later than eight-cell stage, said
policy in the Court's rejection of the district court's view in Jeweller's Circular Publishing was to prevent
a monopoly over public domain materials. Id.
89 Cf. European Patent Convention, supra note 62, art. 53(b) (disallowing patents for "plant and
animal varieties or essentially biological processes for the production of plants or animals...").
90 Under section 3 of the Act, plant breeders or discoverers of distinctive, uniform and stable plant
varieties are granted proprietary rights for a period not exceeding thirty years. Plant Varieties Act, 1997,
ch. 66, pt. I, § 11. The minimum period of protection for trees and grapevines is twenty-five years, while it
is twenty years for other plants. Id. See also The Plant Varieties and Seed Act was Based on the
Convention for the Protection of New Varieties of Plants, Dec. 2, 1961, available at http://www.unep.org/
gopher/un/unep/elipac/intl leg/treaties/tre-03 10.txt.
91 Harvard/Onco-Mouse, [1990] E.P.O.R. 4. The EPO Examining Division gave the rationale for the
exclusion as follows: "[a]nimal varieties are not an appropriate subject-matter for patent protection". Id. at
7-8. See also Sigrid Sterckx, European Patent Law and Biotechnological Inventions, in BIOTECHNOLOGY,
PATENTS AND MORALITY, supra note 7, at 33.
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oncogene optionally being further defined according to
any one of claims 3 to 10.92
The Technical Board of Appeal overruled the Examining Division's
refusal to grant the patent on various grounds, but required the Division to
consider further whether exploitation of the invention would be contrary to
"ordre public" or morality under article 53(a) of the EPC.93 On remand, the
Examining Division concluded that the invention could not be considered
immoral or contrary to public order. 94 It noted further that the test animal
was :useful in cancer research, and therefore beneficial to mankind.
95
Finally, on November 7, 2001, the EPO Opposition Division ruled that the
patent claim must be limited to "transgenic rodents containing an additional
cancer gene," 96 instead of a transgenic non-mammalian animal. The ruling
considerably narrowed the scope of the claim, not on ethical or moral
grounds, but to encourage competition and facilitate the patentability of
subsequent inventions in the field.
In Singapore, plant and animal variety inventions are patentable. The
Select Committee recommended that Parliament not bar plants and animals
from patentability. 97  This position is consistent with both the TRIPS
agreement, which protects "any invention,, 98 and the U.S. Patents Act, under
which plant varieties are patentable.99 Furthermore, after Oncomouse the
European ban on animal patents seems moot.
The Select Committee in Singapore had justified its recommendation
for plant and animal patents to Parliament on the need to provide incentives
to invest and innovate.'00  This conforms to Singapore's biotechnology
92 See Harvard/Onco-Mouse, [1990] E.P.O.R. at 6.
93 Harvard/Onco-Mouse, [1990] E.P.O.R. 501, 504.
94 Harvard/Onco-Mouse, [1991] E.P.O. 525.
9' Id. at 527.
96 See "Oncomouse'" Opposition Proceedings Resume at EPO, EPO/PREss RELEASE (Nov. 5, 2001),
http://www.european-patent-office.org/news/pressrel/2001_11_07_e.htm.
97 See Stanley Lai, The Singapore Patents Act 1994: Whither Biotechnology Patent Law?, 7
SINGAPORE ACADEMY OF LAW J. 397-98 (1995).
98 Article 27(1) of the TRIPS protects "any invention" as long as it is new, inventive, and susceptible
to industrial application. See TRIPS, supra note 43, art. 27(1).
99 Section 161 of the United States Patent Act protects patents for plants:
Whoever invents or discovers and asexually reproduces any distinct and new variety of plant,
including cultivated spores, mutants, hybrids, and newly found seedlings, other than a tuber
propagated plant or a plant found in an uncultivated state, may obtain a patent therefor, subject
to the conditions and requirements of this title.
Patent Act, 35 U.S.C. § 161 (2002).
'oo See Lai, supra note 97.
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policy. Besides, Singapore would be less competitive if it deviated from the
pro-biotechnology patent policy of the United States and Europe.
Viewed from this perspective, it is highly improbable that
Greenpeace, 101 Howard Florey,10 2  Chakrabarty,10 3  and Harvard
Oncomouse'04 would run afoul of Section 13(3) of the Patent Act. This legal
outcome is not assured, but reflects the expediencies of economic policy.
For instance, if an animal patent were challenged under Section 43(1) of the
Prevention of Cruelty to Animals Act,' °5 it is doubtful that the patent would
be invalidated. The rationale of Harvard Oncomouse10 6 and the policy of
promoting biotechnology research in Singapore would most likely inform
such a decision.
In arguing that Singapore's biotechnology patent policy should steer
clear of moral judgments, Stanley Lai posited that ethics and moral issues
are transitory, and that "moral norms in the field of biotechnology, or at least
the courts' perception of them, are liable to change over time."' 0 7 This
uncertainty is understandably the down side of ethical and moral
considerations and probably explains their negligible influence in shaping
the course of biotechnology patenting. It is becoming increasingly clear that
biotechnology's commercial promise is too bright and its public benefits too
attractive for its fate to be decided by the vagaries of ethics and morality.
It can be gleaned from the foregoing that the morality of human gene
patenting, or the propriety of plant and animal variety patenting, is clearly
outside the ambit of the Committee. It is for the courts and patent examiners
in Singapore to decide on a case-by-case basis, while interpreting the
relevant statutory provisions. It is highly improbable that the Committee
would advise the Parliament to deviate from Greenpeace. This would be
true even if gene or plant and animal patenting were found to be morally
reprehensible or unpopular in Singapore. The only way to remain
competitive in this field is for Singapore to align itself with the major
biotechnology players.
101 Plant Genetic Systems v. Greenpeace, [1995] E.P.O.R. 357.
102 Howard Florey, [1995] E.P.O.R. 541.
'03 Diamond v. Chakrabarty, 447 U.S. 303 (1980).
'04 Harvard/Onco-Mouse, [1991] E.P.O.R. 525.
'05 It is an offence punishable with fines not exceeding USD 500 or imprisonment not exceeding 6
months or both. Prevention of Cruelty to Animals Act § 43 (2).
10 Harvard/Onco-Mouse, [1991] E.P.O.R. 525.
107 See Lai, supra note 96, at 346-47 (explaining that patents for contraceptive inventions were
refused on morality grounds).
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IV. FOSTERING THE ETHICS OF BIOMEDICAL RESEARCH IN SINGAPORE
The Committee is to be guided by the imperatives of protecting "the
rights and welfare of individuals" and promoting the realization of
biomedical science's "full potential in Singapore, and for the benefit of
humankind." 108 The terms of reference are:
1. Examine legal, ethical, and social issues, arising from
research on human biology and behavior and its
applications; and
2. Develop and recommend policies to the Life Sciences
Ministerial Committee on legal, ethical and social
issues109
The Committee has the task of laying the groundwork for a
prosperous Singaporean biotechnology industry that is fully responsive to
people's rights and welfare. Simultaneously, the Committee is charged with
fostering certain legal, ethical, and social norms that are both supportive of
the industry's growth and protective of public interests.
This article explores how this task might be accomplished within
Singapore's ethical and legal framework and in the larger context of varied
global perceptions of the biotechnology industry. The following are high
priority items for policy makers.
A. Stem Cell Research and Human Cloning
Human stem cells are unspecialized cells with the potential to renew
themselves, and differentiate into other cell types in the human body."10
There are three types of stem cells: adult, fetal, and embryonic."' Adult
stem cells "are cells that can be isolated from adult tissues such as body,
brain, intestine, skin, bone marrow, muscle and fat."' 12  Though recent
research has shed light on the great potential of adult stem cells isolated
l08 See Bioethics Advisory Committee, http://www.bioethics-singapore.orgfbac/index.jsp.
109 Id.
"n0 See Bioethics Advisory Committee, FAQ, Stem Cells, http://www.bioethics-singapore.org/bac/
detailed.jsp?artid=l 5&typeid=2&cid=22&bSubmitBy=false.
111 Id.
112 Bioethics Advisory Committee, FAQ, Stem Cells, Embryonic Stem Cells, http://www. bioethics-
singapore.org/bac/detailed.jsp?artid=17&typeid=2&cid=24&bSubmitBy=false.
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from bone marrow, 1 3  embryonic stem cells have greater promise in
research. This promise is due to their inherent ability to develop into almost
all of the cell types of the body, such as "the muscle, nerve and blood."'"14
For instance, Israeli scientists have grown heart tissue from human embryo
stem cells, while others in the United States have used stem cells to produce
insulin."1
5
Singapore has made considerable progress in research on embryonic
stem cell research. For instance, Singapore has six of the estimated sixty
embryonic stem cell lines." 6 Though this figure trails some countries, such
as Sweden'1 7 with nineteen, Singapore will undoubtedly improve in this
area.' 8 Stem cell research is arguably one of the most controversial aspects
of biotechnology. Since the creation of Dolly in 1997,19 speculation is rife
that human cloning is afoot.
In Singapore, the immediate response of the National Medical Ethics
Committee12  at it's meeting in June 1997 was that there should be a total
ban on human cloning. From the United States, 122 Germany, 12
3 Taiwan,124
113 According to Gwen Lee, scientists can now cultivate both bone and cartilage cells and are close to
the point of growing "specific tissues such as kidney, liver, and heart-muscle cells." Lee, supra note 2.
14 The scientific terminology for this unique quality is "pluripotentiality." See Bioethics Advisory
Committee, FAQ, Stem Cells, Embryonic Stem Cells, http://www.bioethics-singapore.org/bac/detailed.
jsp?artid=17&typeid=2&cid=24&bSubmitBy=false. Embryonic stem cells may be derived by applying the
following four methodologies: human embryo created by in vitro fertilization (a method of infertility
treatment), where excess embryos could be voluntarily donated by couples who have no need for them, and
who would not want the embryos to be used otherwise; human fetal tissue, following an elective abortion
or miscarriage; human embryos created by in vitro fertilization with sperm and eggs donated mainly for
research purpose; and human or hybrid embryos generated asexually by somatic cell nuclear transfer of
adult human cell nucleus into an enucleated human or animal egg (therapeutic cloning). Id.
..5 Tim Radford, Stem Cells Turned Into Heart Tissue, GUARDIAN UNLIMITED, Aug. 2, 2001,
http://www.guardian.co.uk/genes/article/0,2763,530902,00.html.
116 See Lee, supra note 2, at 14.
17 Swedish Government Says Yes To Therapeutic Cloning, Posting of Human Genetic Engineering,
Human-GE@iatp.org (Feb. 8, 2002) (on file with author).
18 A solid academic and industry research base (actively funded and encouraged by the government)
already exist in Singapore to facilitate greater scientific advancements in this field. See supra Part I; notes
5-7.
19 Dolly is the name given to the sheep cloned by scientists at the Roslin Institute, Edinburgh,
Scotland in 1997. See Campbell et al.; 1. Wilmut et al., supra note 27. Dolly was created through a
technique that involves the transfer of the nucleus of a cell to an unfertilized egg whose genetic materials
are removed. Id. The egg cell and the "reconstructed embryo" are activated to grow by a short electric
impulse. Id. The embryos are then cultured in the lab for 5-6 days before being implanted into a surrogate
ewe. Id.
120 The National Ethics Committee (NMEC) was established in January 1994 as the national authority
to assist the medical profession in addressing ethical issues in medical practice and to ensure a high
standard of ethical practice in Singapore. It is instrumental to several ethical guidelines, to facilitate the
making of sound ethical decisions by medical professionals in clinical practice. See NATIONAL MEDICAL
ETHICS COMMITTEE, NATIONAL MEDICAL ETHICS COMMITTEE: A REVIEW OF ACTIVrIEs 1, 1994-1997,
available at http://www.moh.gov.sg/nmec/NMEc94_97.pdf.
121 However, the cloning of DNA and human cells in culture was to continue. Id. at 11.
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India,'2 5 Australia,126 Sweden, 127 and the United Kingdom, 128 the political
and ethical objection to human reproductive cloning is unanimous, though
acceptance of therapeutic cloning remains an open issue.' 29 The Committee
has recommended that cloning or copying of human beings be banned, but
that research on human stem cells be allowed. 130  The Committee also
recommended that, consistent with other countries,' 3  a Statutory Board be
put in place to oversee stem cell research.
32
The ethical and moral objections to embryonic stem cell research and
human cloning range from scientists wanting "to play God"'133 to the
destruction of embryos, which some regard as humans. 34 The perception of
embryos as humans has brought the concept of personhood to the forefront
122 The Bush administration is opposed to human cloning. See supra note 57 and accompanying text.
Stem cell research for therapeutic purposes is allowed under prescribed conditions. Id. The House of
Representative has voted to ban all forms of cloning; whether therapeutic or reproductive. Id. Some states,
like California, already have laws in place against human cloning. See America's Next Ethical War,
EcONOMIST.COM, Apr. 12, 2001, at http://www.economist.con/PrinterFriendly.cfin?Story_ID=568825.
123 Authorities in Germany still prohibit human cloning, but allow for limited embryo stem research.
See Schiermeier, supra note 56.
124 Authorities in Taiwan haved banned human cloning, but allowed limited stem cell research. See
Taiwan Bans Human Cloning in Stem Cell Research, supra note 55.
125 In India, the government has crafted rules that prohibit human cloning. Kalpana Jain, Government
Drafts Rules Banning Human Cloning, TIMES OF INDIA, Feb. 2, 2002.
126 Human cloning is prohibited in Australia. See NATIONAL HEALTH AND MEDICAL RESEARCH
COUNCIL, AUSTRALIAN HEALTH ETHICS COMMITTEE, SCIENTIFIC, ETHICAL AND REGULATORY
CONSIDERATIONS RELEVANT TO CLONING OF HUMAN BEINGS 2 (1999).
121 On January 29, the Government of Sweden, one of the leading countries in stem-cell research,
declared that it favored cloning early-stage embryos for therapeutic purposes and was set to effect
legislative amendments to reflect this policy. See Swedish Government Says Yes To Therapeutic Cloning,
posting of Human Genetic Engineering, supra note 117. Though human cloning remained banned, the
Social Affairs Minister was quoted as follows: "We have a positive view of somatic cell transfers on
condition that they are done in ethically acceptable forms." Id.
128 See supra note 54 and accompanying text.
129 There are two types of cloning: therapeutic and reproductive. See Bioethics Advisory Committee,
FAQ, Human Cloning, at http://www.bioethics-singapore.org/bac/detailed.jsp?artid=14&typeid = 2&cid=
17&bSubmitBy-false. "Therapeutic cloning is the production of cloned cells to produce tissues and or
organs mainly to improve health care treatments." Id. The technique can be applied to produce human
proteins, replacement tissues, and organs, and cell-based therapies for chronic diseases where there is cell
damage. Id. "Reproductive cloning results from the placement of a cloned embryo into the womb of a
surrogate mother, to allow for pregnancy and a live birth." Id. It could be very useful in animal farming
and for the preservation of endangered animal species. Id. Several animal species such as sheep, pigs,
cows and bulls have been cloned in recent times. Id. The first of such species was a sheep known as
"Dolly." Id. Human reproductive cloning is at present considered morally reprehensible and scientifically
unacceptable by many governments and scientists respectively. Id.3 NATIONAL MEDICAL ETHICS COMMITTEE, supra note 118.
131 Such countries include the United States, United Kingdom, Canada, and others.
132 See Chan Kay Min, Statutory Board Right Move: Stem Cell Researchers, STRAITS TIMES
INTERACTIVE, Jan. 14, 2002, at http://straitstimes.asial.com.sg/cybemews/story/0,1870,96409-10110
45540,00.htrml?.
133 See ANDREW & NELKIN, supra note 34.
134 For example, many religious leaders and religious groups regard embryos as humans.
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of recent bioethics discourse, 135 and challenged the conventional legal
concept of embryos.' 36 For example, a French Judge ruled on July 5, 1995,
that a fetus was a "future human being, already alive,"' 37 while the Supreme
Court of Canada ruled in 1999 that allowing children to sue their mothers for
prenatal injuries caused by those mothers' negligence would violate the
rights of pregnant women and "result in very extensive and unacceptable
intrusions to the bodily integrity, privacy, and autonomy of rights of
women."' 138  Since the ruling did not expressly foreclose the fetus' locus
standi to sue, there was implicit in the ruling a recognition of the personhood
of the fetus or embryo. The branding of embryos and fetus as persons is the
basis of pro-life advocates' objections to embryonic stem cell research. 39
Of equal importance is the danger that the market for embryos will be
commercialized. 146 For instance, the National Institute of Health in the
United States expressly prohibits the use of inducements, monetary or
otherwise, for the donation of embryos, and emphasizes the distinction
between fertility treatment and the decision to donate embryos for
135 See Sahin Aksoy, Personhood, A Matter of Moral Debates, EUBIOS J. ASIAN & INT'L BIOETHICS
3-4 (1997). The author highlighted philosophical and monotheistic religions' contention of the separate
existence of the 'soul' without which there could be no 'body', to canvass for determining the exact time of
"ensoulment". Id. This, he believed, was the key to ascertaining when life came into being, and a proper
understanding of this could put an end to termination of "human persons", such as performing abortions.
Id. See also Jason T. Eberl, The Beginning Of Personhood: A Thomistic Biological Analysis, 14 BIOETHICS
134-53 (2000). Using a Thomistic hypothesis that human person is a composite of a biological organism
and intellective soul, the author posited that "the beginning of an individual human biological organism
occurs at the moment when implantation of the zygote in the uterus occurs and the 'primitive streak' begins
to form." Id. According to Eberl, this has serious "moral implications on the status of pre-implantation
biological cell clusters." Id.
136 Singapore's Penal Code (1985) does not define "human being". Section 45 defines life as the life
of a human being. Section 10 defines "man" as a male human being, while a "woman" is defined as a
female human being. Since it is impossible to determine the sex of an embryo, it cannot be properly
regarded as a human being under the Penal Code.
137 See Marc Gozlan, Amnesty Denied to French Anti-Abortion Protestors, 346 LANCET 111 (1995).
138 Dobson (Litigation Guardian of) v. Dobson, [1999] D.L.R. (4"h) 1. Implicit in this ruling is the
notion that the conception was already a person. See id. The ruling overruled a New Brunswick Court of
Appeal decision that allowed six-year-old Ryan Dobson the retroactive right to sue-his mother for injuries
incurred in a car accident. Id.
139 For instance, at the heart of cell stem research debate in the United States is the conflict over when
life begins. President Bush's contention, (which is shared by many pro-life groups in and outside the
United States) is that "the embryo from which a stem cell is harvested is a human being." See Bush Calls
on Senate to Ban Human Cloning (Fox News Channel broadcast, Apr. 10, 2002), available at
htpp://www.foxnews.com/story/0,2933,50004,00.btml. President Bush wanted the U.S. Senate to enact a
Bill (like the House of Representative did in 2001) that would completely prohibit all forms of stem cell
research-both therapeutic and reproductive. Id. According to Bush, "Life is creation, not commodity ....
Advances in new biotechnology must never come at the expense of human conscience .. . it would be a
mistake for the U.S. Senate to allow any kind of human cloning to come out of that chamber." Id.
140 In South Africa, this debate intensified when it was learned that placentas were sold to a French
company. See BMJ 311 (1995), cited in Embryo Status News, available at http://www.biol.tsukuba.ac.jp/-
macer/NBB/NBBEM.html.
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research.141  Whatever the general attitude might be towards stem cell
research, it is clear that Singapore will press ahead with embryonic stem cell
research. This is good news for the biomedical community, but the
Committee must develop a means of preventing abuse and protecting "the
rights of the individuals.' 42
Along these lines, the Ministry of Health in Singapore has guidelines
regulating the practice of human embryology and in-vitro fertilization.
1 43
The guidelines prohibit the sale of embryos and require the informed,
uncompensated consent of donors.44 It is preferable, however, to have these
ethical guidelines enacted into law by Parliament to clarify the scope of
individual rights and create criminal sanctions for wrongdoing. The United
Kingdom, for instance, has adopted the Human Fertilization and
Embryology Act. 145  The Act clearly defines the rights and limits of all
parties and creates penalties for violations of the statute. 146  The United
Kingdom has also enacted the 2001 Human Reproductive Cloning Act,
which criminalizes the placement of a human embryo, which has been
created by means other than fertilization, in a woman. The statute provides a
maximum penalty of ten years imprisonment, a fine, or both.147  This is a
clear signal that human cloning is unlawful in the United Kingdom.
Singapore would do well to follow this example.
It does not necessarily follow, however, that government prohibitions
on cloning have eliminated demand for the technology. 48  This has given
rise to the theory of a reproductive right in cloning and the argument that the
141 Compliance with these guidelines is enforced by the requirement that a request for National
Institute of Health ("NIH") funding for research using these cells must include a signed assurance that the
cells were derived from human embryos or fetal tissue in accordance with these guidelines. See NIH Fact
Sheet on Human Pluripotent Stem Cell Research Guidelines, NATIONAL INSTITUTE OF HEALTH, available
at http://www.nih.gov/news/stemcell/ stemfactsheet.htm.
42 Bioethics Advisory Committee, Introduction, Terms of Reference, http://www.bioethics-
singapore.org/bac/introduction.jsp.
'41 See Ministry of Health, Guidelines On Human Embryology and the Practice of Reproductive
Technologies in Singapore.
14 id.
14 Human Fertilization and Embryology Act, 1990, available at http://www.hmso.gov.uk/actsl990/
Ukpga 19900037 en 2.htm.
' For instance, a person who creates an embryo or keeps or uses an embryo without a license would
be guilty of an offence, and upon conviction, liable for a maximum of two years imprisonment or a fine or
both. Id. at § 41(4)A.
147 Id. at § 1(l)(2).
148 For instance, an Italian scientist, Dr. Severino Antinori, recently announced at a conference in
Dubai that a woman was pregnant with a cloned baby, the "son of a rich Arab." See Ananova, First cloned
baby is son of rich Arab, Apr. 7, 2002, available at http://www.ananova.com/youmews/story/
sm_561586.html.
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right to clone is constitutionally guaranteed.'49 It would be interesting to see
anti-cloning laws around the world challenged on constitutional grounds of
free speech, related to scientific enquiries and reproductive rights.
In Singapore, challenging embryonic stem cell research and cloning
on constitutional grounds would be a futile academic exercise. Assuming
for the sake of argument that a human embryo is a person,150 then research in
embryos would violate section 9(1) of the Constitution of the Republic of
Singapore,15' which provides that no "person shall be deprived of his life or
personal liberty save in accordance with law," or section 10(1) which
prohibits slavery. Conversely, aggrieved scientists might challenge a ban on
human cloning as an infraction of their rights to make scientific enquiries as
guaranteed by section 14(1)(a) of the Constitution. Of course, these
analogies are far fetched. But should they ever arise, it is clear which view
the courts would take.
B. Ownership and Sourcing of Genetic Materials
Another hotbed of ethical and moral controversies in biotechnology is
the ownership of and prospecting for human genetic materials. In Moore,'52
the defendant had developed a patented cell line worth millions of dollars,
based on the plaintiff's genetic material without his knowledge or consent.
The Supreme Court of California, relying on the Health and Safety Code,
which prohibited patients' ownership interest in excised body parts, 53 held
that the plaintiff had no property right in his excised cells. Consequently, he
had no claim to the patented cell lines. The court also reasoned that
allowing such ownership could stifle biomedical research. However, after
Moore, the California Legislature enacted a tissue-specific bill, which
prohibits the stealing of human eggs, sperm, or embryos.
Similarly, the question of ownership arose in Del Zio v. Manhattan's
Columbia Presbyterian Medical Center.'55 In Del Zio, the ovum and sperm
of a couple were destroyed in the course of in-vitro fertilization. The court
held that the woman had no property interest in the destroyed material, but
149 See Lori B Andrew, Is There A Right To Clone? Constitutional Challenges To Ban On Human
Cloning, 1 HARv. J.L. & TECH. 647, 676 (1998).
For a discussion of the French and Canadian rulings, respectively, see supra notes 135, 136 and
accompanying text.
SINGAPORE CONST. (1963, revised 1985, 1999).
'sz Moore v. Regents of the Univ. of Cal., 793 P.2d 479 (Cal. 1990).
3 CAL. HEALTH AND SAFETY CODE §§ 7001, 4054.4.
154 See ANDREWS & NELKIN, supra note 34, at 164.
' No. 74-35558, US. Dist. Lexis 14450 (SDNY, 1978).
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she was awarded USD 50,000 damages for emotional distress. 156 However,
in Whaley v. Tuscola,' 57 it was held that relatives had a constitutionally
protected property interest in the dead body of a relative. In the same vein,
in Brotherton v. Cleveland,1 58 a widow successfully sued an Ohio hospital
for removing her dead husband's cornea without her consent. Although
Moore and similar cases follow the traditional common law approach,' 59 it
now seems that courts in the United States are recognizing proprietary
claims to body parts.
In the context of modem commercially-driven biotechnology,
however, there is an increasing demand for a formula for appropriate sharing
of benefits between individual donors and researchers. In India, for
example, the Committee under the Department of Biotechnology
recommended in February 2002 that "though human material in its natural
state cannot be the subject of a direct financial gain ... if any commercial
use were to be made of the biological samples, appropriate benefit-sharing
agreements would need to be made."
60
This reflects the mantra that dominates the discourse on trade and
politics. The South demands acknowledgement of genetic sources in patent
specifications or claims, as well as adequate remuneration for use of genetic
material. It also demands that the provisions of the TRIPS agreement be
aligned with that of the Rio Biodiversity Convention.'6 ' The bio-
prospecting activities of biotechnology companies are often deprecated as
"bio-feudalism" that is designed to make "bioserfs" out of developing
countries. 62 For example, the Neem tree in India, which has been used
pharmaceutically and agriculturally for centuries, became the subject "of
sixty-five patents filed by U.S. and European companies."' 63 This is no more
than robbing the public domain. It is feasible because the conventional
patent regime largely ignores such traditional uses as part of the prior art that
could render the Neem tree and similar patents either unpatentable or invalid
due to lack of novelty.
164
156 Id.
is 58 F.3d 111, 112, 116, (6th Cir. 1995).
'ss 923 F.2d 477 (6th Cir. 1991).
'59 For a very detailed discussion of these cases, see Terry, Kaan Sheung-Hung, Rights, Ethics And
The Commercialization Of The Human Body, SING. J. LEGAL STUDIES 483-508 (2000). See also N.
Remigius Nwabueze, Biotechnology and the New Property Regime in Human Bodies and Body Parts, 23
LOYOLA L.A. INT'L& COMP. L. REv. 19 (2001). "
160 See Jain, supra note 125.
16' For a detailed discussion of these issues, see Vandana, supra note 3 1.162 ld.
163 Id. See also ANDREWS & NELKIN, supra note 34, at 71.
'64 For instance, under the United States Patent Act, 35 U.S.C.A § 102, the prior art comprises the
actual use of an invention, a previous patent or a written description of the invention in the United States or
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Blood and other body samples are randomly taken from poor people
around the world for genetic screening and the subsequent patenting of new
drugs, diagnostic tests, bioengineered substances, or valuable genetic traits
derived from them.' 65  Such screenings are characteristically without
informed consent of their subjects. Between 1990 and 1991, the U.S.
government filed for patents on genes from Melanesians in the Solomon
Islands, cell lines from a Guyami woman in Panama, and genes of a Hagahai
man from Papua, New Guinea.' 66 The ethical and moral issues raised here
are patently clear: from Moore down to the Hagahai man, the moral and
ethical propriety of genetic prospecting is clearly reprehensible.
In Singapore, trade in human blood is prohibited. Section 4(1)(a) of
the Private Hospitals and Medical Clinics Act provides:
No person shall: (a) buy or offer to buy or (b) sell, or offer to
sell human blood or right to take blood from the body of
another person. 167
Violation of this Section is punishable by a maximum fine of SGD 20,000,
or imprisonment for a term not exceeding two years, or both. 68 Similarly,
section 14(1) of the Human Organ Transplant Act' 69 prohibits trading in
organs and blood. A contract in violation of this statute is void, and
violators are subject to a fine not exceeding SGD 10,000, or to imprisonment
for a term not exceeding a year, or to both.1
70
The provision of section 14(4) is instructive. It exempts from
prohibition the sale of "a specified class or classes of product derived from
any organ or blood that has been subjected to processing or treatment." This
protects biotechnology products derived from organs and blood samples
including patented biotechnology products.'71
A similarly favorable provision is section 16(1) of the Human Organ
Transplant Act. Intended to promote organ transplants, it is no more than a
a foreign country. In India for example, traditional pharmaceutical products and medicine ("ayurveda") is
based largely on unwritten traditional knowledge that has survived successive generations. See Edna
Fernandes, Alternative Medicine, Ancient Cures in a Global Market, Fin. Times, Apr. 30, 2002, at 11.
Such uses do not form part of the prior art in the United States. Id.
165 See ANDREw & NELKIN, supra note 34, at 71.
166 See id. The United States, however, withdrew the Guyami and Solomon Islands patents under
pressure in 1995. Id.
167 Private Hospitals and Medical Clinics Act, 1980, ch. 248 (Sing.).
168 Id,. ch. 248, § 4(2).
'
69 d,. ch. 131, A (1987).
170 /Id,. ch. 131,§ 14(2).
171 Id.
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codification of Moore. Though express or implied consent is required for
the removal of any organ from the body of a living person in the course of
an operation or treatment, there is no a statutory penalty for failure to obtain
consent, nor does lack of consent vitiate the subsequent use of the removed
organ. This pro-biomedical research law is undoubtedly intended by
Parliament to encourage research.
As noted earlier, the Committee has the duty to create a policy that
both promotes biotechnology research and protects the rights and welfare of
individuals. This is a delicate balancing act. Consequently, it is suggested
that Singapore should adopt an enforceable regime that punishes lack of
informed consent in biomedical research, though this would not necessarily
invalidate the use of any organ derived under such circumstances.
Another pertinent issue that the Committee should address is
compensation for the subjects of medical research. Is it fair for the human
subjects to get nothing from products freely derived from their bodies? Is
Moore good policy in today's multi-billion dollar biotechnology
industries? 72  What is wrong with getting paid for organs that could
potentially save thousands of lives in pharmaceutical and medical products?
Or is it in the interest of the "rights and welfare of the individuals"?
C. Genetic Testing and Discrimination
Genetic or DNA testing allows the detection of predisposition to many
genetic diseases. The diagnostic kits for genetic testing are usually patented,
and testing is usually done with the consent of the patentee, subject to the
payment of licensing fees. Patenting of genetic tests therefore contributes to
higher health care costs.
According to Ricarda Steinbrecher, "for the best health care,
discovery about genes must be freely available, not just exclusively to profit
the drug companies."'' 73 Sue Mayer underscored the real problem:
"[C]ompanies are getting greedy, and the NHS could be bankrupted by
having to pay royalties for gene tests and drugs."'174  In response, public
172 Moore v. Regents of the Univ. of Cal., 793 P.2d 479 (Cal. 1990).
173 See Patenting Genes-Stifling Research and Jeopardizing Healthcare, GENEWATCH, available at
http///www.genewatch.org/HumanGen/PressReleases/prl8.htm. Another adverse effect of gene patenting
is that it could stifle research. See James Meek, Doctors Hindered By Company's Gene Patent, GUARDLAN
UNLIMITED, Feb. 7, 2002, available at: http://www.guardian.co.uk/genes/article/0,2763,646089,00. html.
The high-level secrecy of data protection is fueled by the race for patents. Id. Data hoarding could cripple
research since it is bound to constrain the flow of scientific information. Id. See also Merz, Jon F, et al,
Diagnostic Testing Fails The Test, NATURE 415, 577-579 (2002) (finding that U.S. laboratories have
refrained from offering clinical-testing services for haemochromatosis because of patents).
114 See ANDREWS & NELKIN, supra note 34.
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interest groups in the United States have opposed the first patent for
diagnostic test kit for breast cancer genes, marketed by Myriad at a cost of
USD 2,000. An absolute monopoly was alleged to be unfavorable to public
interest.175
As noted, the Committee has no authority over gene patenting. It is
the prerogative of patent examiners and courts to determine the patentability
of genes against the background of patent law requirements. But the
Committee could certainly make recommendations to limit predatory
marketing by companies that could inflate healthcare costs in Singapore.
This would amount to a balancing act between the interests of rich
biotechnology companies and ordinary citizens. The situation would be a
good instance for protecting the "rights and welfare" of the people.
Another dimension to genetic testing is its potential for discriminatory
use in employment and insurance, as well as the attendant privacy
implications. "7 Apart from the adverse psychological effects on the
individual, the revelation that one is predisposed to cancer, for instance,
might lead to an adverse employment decision even though the disease
might not appear for many years. According to Barbara Katz Rothman,
"with genetic testing for the breast cancer gene, a three-year-old girl can
have a diagnosis of breast cancer before she even has breasts."' 177
Though the triggering of a genetic disease could depend on certain
environmental factors or habits, the general perception of genetic diseases is
they are largely governed by genetic determinism. This perception discounts
the possible contribution of the environment and other factors that the
individual cannot control. 178 Also, the advent of gene therapy has led to the
prospect of "designer babies," and fueled speculations that the problem of
eugenics will reemerge. 179 For instance, Chicago doctors recently helped a
thirty year-old woman give birth to a baby free from her family's early
Alzheimer's disease. The doctors had used sophisticated genetic tests on
batches of human eggs. Without this screening, the newborn had a 50%
chance of becoming senile by the age of forty. The feat was branded as "the
latest step toward designer babies and . . . evidence of a trend toward
171 See Caroline Ryan, Demand For Gene Patent Rethink, HUMAN GENETIC ENGINEERING NEWS
CLIPPINGS, Feb. 18, 2002.
176 See ANDREWS & NELKIN, supra note 34, at 83
'7Id. at87.
178 See Justine Burley, Bad Genetic Luck and Health Insurance, THE GENETIC REVOLUTION AND
HUMAN RIGHTS 56 (Justine Burley ed., 1999).
179 See Symposium, Human Genome Human Being, ACADEMY OF SCIENCES (Feb. 25, 2002),
available at http://www.calacademy.org/symposia/hghb. See also ALLEN BUCHANAN ET AL., FROM
CHANCE TO CHOICE: GENETICS AND JUSTICE (2000).
JUNE 2002
PACIFIC RIM LAW & POLICY JOURNAL
intolerance of human imperfection."'i8 0 It is feared that eugenics, which is
concerned with improving the quality of human stock, could negatively
impact the handicapped and foster a feeling of societal rejection.'
8
'
These issues raise fundamental human rights questions. In response,
some governments have enacted specific legislations prohibiting
discrimination based on genetic information, especially in insurance and the
work place. In the United States, for example, Congress has considered the
Genetic Nondiscrimination in Health Insurance and Employment Act (S.
318 & H.R.602). The bill would prohibit the use of genetic information in
determining eligibility for insurance or adjusting of premium rates. It would
also forbid a health insurer from requesting, requiring, collecting, or
purchasing protected genetic information concerning an individual. 182 Also,
some states have enacted laws prohibiting genetic discrimination.1
83
Furthermore, both the United Nations Economic and Social Council's
(UNESCO) Universal Declaration on Human Genomes, and the Europe
Convention on Human Rights and Biomedicine, prohibit discrimination
based on genetic characteristics intended to infringe or that does infringe
upon human rights, fundamental freedoms, and human dignity.
184
Though section 12(2) of Singapore's Constitution prohibits
discriminatory practices against citizens on grounds of religion, race,
descent, or place of birth, there is no express prohibition against genetic
discrimination. The Committee should recommend to Parliament specific
legislation that is similar to the proposed United States genetic
nondiscrimination law or that embodies the ideals of the UNESCO
Universal Declaration on Human Genome and the European Convention on
Biomedicine. Such legislation is sure to uphold the "rights and welfare" of
the people.
'go See Rick Weiss, Alzheimer's Gene Screened From Newborn, WASH. POST, Feb. 27, 2002, at AI.
See also James Meek, Baby With Selected Gene Born In Britain, GUARDIAN, Feb. 16, 2002. The baby had
a desired genetic characteristic known in advance of her birth. Id. She was designed with" extra gift cells
capable of saving her older brother if he suffers a relapse into leukemia." Id.
181 See Simon Mawer, Eugenics, BBC GENE STORIES-GENES AND HISTORY-EUGENICS, available at:
http://www.bbc.co.uk/print/history/genes/eugenics/intro.html.
182 The full text of the bill is available at the University of Houston Law Center's website,
http://www.law.uh.edu/healthlawperspectives/Genetics/01083 IHealthlns.html.
183 These include: Alabama (ALA. CODE SS 27-21 A-7, 27-52-20, 27-53-1 et sec.), California (CAL.
HEALTH & SAFETY CODE §1374.7), Florida (FLA. STAT. ANN. §627.4301.34075), and Michigan (MICH.
COMP. LAWS ANN. § 500.34075).
184 See the Universal Declaration on the Human Genome and Human Rights, arts. 1-7, available at:
http://www.unesco.org. See also the Europe Convention On Human Rights and Biomedicine (1997),
available at http://www.press.coe.int/cp/97/173a%2897%29.htm.
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V. CONCLUSION
The biotechnology industry unquestionably holds great promise for
humanity. From boosting food production to improving the quality of
healthcare, it is arguably the science to watch in the twenty-first century.
But then, the risks of biotechnology may be as incalculable as its promise.
Though several ethical and moral issues remain unanswered, it is too
early to announce their failure in reining in the biotechnology revolution. At
least for now there are limited successes; human cloning has been put on
hold and genetic discrimination has been outlawed. But, there are limited
failures as well. Ethics and morality are too weak to contain gene and
organism patenting, while the exploitation of human and other genetic
resources remains largely unacknowledged and uncompensated.
Whether ethical and moral considerations are weak or not, they will
linger as long as there is biotechnology. "Bioethics," after all, is about
bringing responsibility and accountability to science. That is precisely what
the Bioethics Advisory Committee in Singapore is set to do.

